Release Summary

Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to a Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.

Spectrum Pharmaceuticals